Heston S, Hurst J, Kelly M
Expert Rev Anti Infect Ther. 2024; 22(7):529-545.
PMID: 38605646
PMC: 11464204.
DOI: 10.1080/14787210.2024.2340664.
Liu A, Gundacker H, Richardson B, Chen B, Hoesley C, van der Straten A
J Int AIDS Soc. 2024; 27(3):e26223.
PMID: 38444118
PMC: 10935712.
DOI: 10.1002/jia2.26223.
Weld E, McGowan I, Anton P, Fuchs E, Ho K, Carballo-Dieguez A
J Infect Dis. 2023; 229(4):1131-1140.
PMID: 38019657
PMC: 11011183.
DOI: 10.1093/infdis/jiad535.
Roberts S, Mancuso N, Williams K, Nabunya H, Mposula H, Mugocha C
J Int AIDS Soc. 2023; 26(11):e26189.
PMID: 37936551
PMC: 10630658.
DOI: 10.1002/jia2.26189.
Young I, Srinivasan P, Shrivastava R, Janusziewicz R, Thorson A, Cottrell M
Biomaterials. 2023; 301:122260.
PMID: 37549505
PMC: 11537264.
DOI: 10.1016/j.biomaterials.2023.122260.
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
Mugo N, Mudhune V, Heffron R, Thomas K, McLellan-Lemal E, Njoroge B
Front Reprod Health. 2023; 5:1118030.
PMID: 37383290
PMC: 10293630.
DOI: 10.3389/frph.2023.1118030.
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman A, Ouattara L, Yousefieh N, Anderson P, Bushman L, Fang X
Front Cell Infect Microbiol. 2023; 13:1130101.
PMID: 37153145
PMC: 10154607.
DOI: 10.3389/fcimb.2023.1130101.
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Abdool Karim Q, Archary D, Barre-Sinoussi F, Broliden K, Cabrera C, Chiodi F
Front Immunol. 2022; 13:1055042.
PMID: 36561760
PMC: 9763292.
DOI: 10.3389/fimmu.2022.1055042.
Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.
Zondo N, Sobia P, Sivro A, Ngcapu S, Ramsuran V, Archary D
Front Genet. 2022; 13:940661.
PMID: 36246609
PMC: 9557974.
DOI: 10.3389/fgene.2022.940661.
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Thurman A, Brache V, Cochon L, Ouattara L, Chandra N, Jacot T
PLoS One. 2022; 17(10):e0275794.
PMID: 36215267
PMC: 9550080.
DOI: 10.1371/journal.pone.0275794.
The pharmacology of HIV-1 antiretrovirals differs between macaques and humans.
Herrera C, Cottrell M, Prybylski J, Kashuba A, Veazey R, Garcia-Perez J
iScience. 2022; 25(6):104409.
PMID: 35663021
PMC: 9157191.
DOI: 10.1016/j.isci.2022.104409.
Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman A, Ravel J, Gajer P, Marzinke M, Ouattara L, Jacot T
Front Cell Infect Microbiol. 2022; 12:799501.
PMID: 35350436
PMC: 8957918.
DOI: 10.3389/fcimb.2022.799501.
HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.
Stewart J, Baeten J
Nat Rev Urol. 2021; 19(1):7-15.
PMID: 34697493
PMC: 9249100.
DOI: 10.1038/s41585-021-00527-4.
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten J, Palanee-Phillips T, Mgodi N, Mayo A, Szydlo D, Ramjee G
Lancet HIV. 2021; 8(2):e87-e95.
PMID: 33539762
PMC: 8038210.
DOI: 10.1016/S2352-3018(20)30304-0.
The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly M, Sterling M, Holder A, Dinh C, Nishiura K, Khalil G
Antiviral Res. 2021; 186:105001.
PMID: 33385420
PMC: 8480307.
DOI: 10.1016/j.antiviral.2020.105001.
Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.
Fisher K, Mabuka J, Sivro A, Ngcapu S, Passmore J, Osman F
Front Immunol. 2020; 11:1274.
PMID: 32733445
PMC: 7357346.
DOI: 10.3389/fimmu.2020.01274.
HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition.
Liebenberg L, McKinnon L, Yende-Zuma N, Garrett N, Baxter C, Kharsany A
Nat Commun. 2019; 10(1):5227.
PMID: 31745084
PMC: 6863918.
DOI: 10.1038/s41467-019-13089-2.
Topical Microbicides in HIV Prevention: State of the Promise.
Baeten J, Hendrix C, Hillier S
Annu Rev Med. 2019; 71:361-377.
PMID: 31613684
PMC: 8038211.
DOI: 10.1146/annurev-med-090518-093731.
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman A, Schwartz J, Ravel J, Gajer P, Marzinke M, Yousefieh N
PLoS One. 2019; 14(5):e0217229.
PMID: 31107913
PMC: 6527208.
DOI: 10.1371/journal.pone.0217229.
Smart Freeze-Dried Bigels for the Prevention of the Sexual Transmission of HIV by Accelerating the Vaginal Release of Tenofovir during Intercourse.
Martin-Illana A, Notario-Perez F, Cazorla-Luna R, Ruiz-Caro R, Veiga M
Pharmaceutics. 2019; 11(5).
PMID: 31086015
PMC: 6571877.
DOI: 10.3390/pharmaceutics11050232.
